Zealand Pharma soars after positive trial results from weight loss drug By Investing.com
Zealand Pharma soars after positive trial results from weight loss drug…
95,650€
0,95%
Echtzeit-Aktienkurs Zealand Pharma A/S
Bid:
Ask:
Nachrichten zur Zealand Pharma A/S Aktie
Weight loss drug contender Zealand Pharma jumps 23% on trial results
The Danish company is testing a rival to drugs such as Ozempic and Wegovy which it says may deliver a…
Zealand Pharma-Aktie markiert neue Höchststände - Petrelintide im Fokus! Aktienanalyse
Kulmbach (www.aktiencheck.de) - Zealand Pharma-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…
Zealand Pharma und Gubra heben ab: Ist "Amylin" das nächste große Ding nach Wegovy und Co?
Am Freitag verzeichnen die Aktien der beiden dänischen Biotech-Unternehmen Zealand Pharma und Gubra erneut deutliche Zugewinne. Der Grund für den…
Zealand Pharma und Gubra heben ab: Ist "Amylin" das nächste große Ding nach Wegovy und Co?
Am Freitag verzeichnen die Aktien der beiden dänischen Biotech-Unternehmen Zealand Pharma und Gubra erneut deutliche Zugewinne. Der Grund für den…
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Company announcement - No. 30 / 2024…
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
Press release – No. 6 / 2024…
Zealand Pharma major shareholder announcement: Polar Capital
Company announcement – No. 28 / 2024…
Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide
…
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 27 / 2024…
AKTIONÄR-Hot-Stock Gubra: Nächste Kaufwelle rollt - Rekordhoch in Sicht
Der Erfolg von Novo Nordisk mit Wegovy, Ozempic und Co überragt die gesamte europäische Biopharma-Branche. Doch der dänische Kurszettel hat…
AKTIONÄR-Hot-Stock Gubra: Nächste Kaufwelle rollt – Rekordhoch in Sicht
Der Erfolg von Novo Nordisk mit Wegovy, Ozempic und Co überragt die gesamte europäische Biopharma-Branche. Doch der dänische Kurszettel hat…
AKTIONÄR-Hot-Stock Gubra: Nächste Kaufwelle rollt – Rekordhoch in Sicht
Der Erfolg von Novo Nordisk mit Wegovy, Ozempic und Co überragt die gesamte europäische Biopharma-Branche. Doch der dänische Kurszettel hat…
Earnings call: Zealand Pharma reports solid Q1 results, advances in obesity treatment By Investing.com
Earnings call: Zealand Pharma reports solid Q1 results, advances in obesity treatment…
Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript
…
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 25 / 2024…
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
Press Release – No. 4 / 2024…
Amgen, newer rivals could threaten Novo Nordisk and Eli Lillys weight loss drug dominance
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.…
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 23 / 2024…
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024
Company announcement – No. 22 / 2024…
Total number of shares and voting rights in Zealand Pharma at March 31, 2024
Company announcement – No. 21 / 2024…
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 20 / 2024…
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 19 / 2024…
Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment
…
Zealand Pharma major shareholder announcement: Van Herk Investments
Company announcement – No. 18 / 2024…
Zealand Pharmas Annual General Meeting 2024
Company announcement – No. 17 / 2024…
Zealand Pharma major shareholder announcement: Polar Capital
Company announcement – No. 16 / 2024…
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.
The risk is higher, but so is the upside when it comes to Zealand Pharma.…
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 13 / 2024…
Novo Nordisk, Zealand Pharma und Gubra: Trio im Höhenrausch – Zauberwort "Amylin"
Im vergangenen Jahr sagte Gubra-CFO Kristian Borbos im Interview mit dem AKTIONÄR: "Die Entdeckung und Entwicklung von Adipositastherapien sind eine…
Novo Nordisk, Zealand Pharma und Gubra: Trio im Höhenrausch – Zauberwort "Amylin"
Im vergangenen Jahr sagte Gubra-CFO Kristian Borbos im Interview mit dem AKTIONÄR: "Die Entdeckung und Entwicklung von Adipositastherapien sind eine…
ANALYSE-FLASH: Berenberg startet Zealand Pharma mit Buy - Ziel 815 Kronen
HAMBURG (dpa-AFX) - Die Privatbank Berenberg hat Zealand Pharma mit "Buy" und einem Kursziel von 815 dänischen Kronen in die…
ANALYSE-FLASH: Berenberg startet Zealand Pharma mit 'Buy' - Ziel 815 Kronen
HAMBURG (dpa-AFX) - Die Privatbank Berenberg hat Zealand Pharma mit "Buy" und einem Kursziel von 815…
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
Press release – No. 3 / 2023…
Zealand Pharma A/S (ZEAL) Q4 2023 Earnings Call Transcript
…
Zealand Pharma convenes its Annual General Meeting 2024
Company Announcement – No. 10 / 2024…
Zealand Pharma stock soars 35% on strong trial results for its weight loss treatment By Investing.com
Zealand Pharma stock soars 35% on strong trial results for its weight loss treatment…
Abnehmmittel: Boehringers Diätspritze wirkt in Studie auch gegen Fettleber
Der potentielle Konkurrent des Erfolgsprodukt Ozempic von Novo Nordisk wird gemeinsam mit der dänischen Firma Zealand Pharma erforscht. Der Studienerfolg…
Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results
Zealand Pharmas Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity,…
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Company announcement - No. 8 / 2024…
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
Press Release – No. 2 / 2024…
Zealand Pharma major shareholder announcement: Van Herk Investments
Company announcement – No. 6 / 2024…
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
Company announcement – No. 5 / 2024…
Zealand Pharma completes registration of capital increase
Company announcement – No. 3 / 2024…
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
Company announcement – No. 2 / 2024…
Zealand Pharma secures $214 million in private funding By Investing.com
Zealand Pharma secures $214 million in private funding…
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
Press Release – No. 1 / 2024…
Total number of shares and voting rights in Zealand Pharma at December 29, 2023
Company announcement – No. 46 / 2023…
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
Press release – No. 18 / 2023…
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
Press release No. 17 / 2023…